ERBB2 Targeting Reveals a Significant Suppression of Tumorigenesis in Murine Endometrial Cancer with Pten Mutation

Area of Science:

• Gynecologic Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Endometrial cancer is the most common gynecologic malignancy.
• PTEN deficiency occurs in over 50% of primary endometrial cancers, impacting PI3K signaling.
• ERBB2 amplification is implicated in various cancers, but its role in PTEN-mutated endometrial cancer is unstudied.

Purpose of the Study:

• To investigate the therapeutic potential of targeting ERBB2 in endometrial cancer with PTEN deficiency.
• To evaluate the effect of ERBB2 ablation on tumor development and progression in a PTEN-deficient murine model.

Main Methods:

• Development of a Pgr^cre/+Erbb2^f/fPten^f/f (Erbb2^d/d Pten^d/d) murine model.
• Histopathological and molecular analyses were conducted on Pten^d/d and Erbb2^d/d Pten^d/d mice.
• Assessment of tumor development, progression, and cell proliferation rates.

Main Results:

• Erbb2 ablation in Erbb2^d/d Pten^d/d mice significantly reduced endometrial cancer development and progression compared to Pten^d/d mice.
• A notable decrease in the percentage of proliferative cells was observed in Erbb2^d/d Pten^d/d mice, indicating an anti-tumorigenic effect.
• ERBB2 functions as an oncogene in the context of PTEN deficiency in endometrial cancer.

Conclusions:

• ERBB2 ablation demonstrates significant suppression of tumorigenesis in PTEN-deficient endometrial cancer models.
• Targeting ERBB2 represents a promising therapeutic strategy for endometrial cancer with PTEN deficiency.
• This study highlights the potential of ERBB2-targeted therapy to hinder cancer development in this specific patient population.